Since January 1, 2012, a new team of editors has been looking after the journal. The photographs with a very brief summary of research interests are being used here as an introduction for all of our readers (Figure). We are privileged to be able to serve the readers of Hypertension and to follow in the footsteps of an excellent editorial team led by Dr John Hall.1 Indeed, we suspect that you haven't noticed the transition, because our aim has been to make it as smooth as possible.
Hypertension is recognized as the top journal in its field, and the new team thanks all of the previous editors for their vision and hard work, both essential prerequisites to get the journal to this position. Under the previous editorial team, the impact factor grew, and we will make every effort to ensure that this continues. It is up to all of us, including the editorial board and the entire community of contributors and readers, to maintain and develop the excellence of our journal. The main objectives for Hypertension remain very similar to those published by Dr John Hall a few months ago1: (1) to publish the highest quality of original basic and clinical research relating to hypertension; (2) to increase the readership and scientific importance of Hypertension; (3) to provide fair and quick reviews for submitted manuscripts followed by a rapid publication of all accepted articles; and (4) to serve well the international community of hypertension researchers and practitioners and to be an important vehicle for achieving the mission of the American Heart Association.
To achieve these objectives, we have assembled an international team of associate editors who represent 6 countries and 3 continents between them. We are also greatly helped by our consulting editors (Drs Carey, DiBona, Dzau, Ellison, Frohlich, Fujita, Hall, Mark, Navar, and Oparil).
There are several new ideas and initiatives that are being developed together with the American Heart Association. These include several new topical reviews that we commissioned before January 2012, which will cover broad areas of interest, such as microRNAs, regenerative medicine, clinical trials, clinical guidelines, and many other aspects relevant to hypertension clinicians and scientists alike. We have developed a closer editorial relationship with Circulation, which will result in a referral of articles between the 2 journals with a significant benefit to authors and readers. A similar relationship will also be developed with the online American Heart Association journal, Journal of the American Heart Association. Other plans include a presence on Facebook and Twitter, as well as the iPad application or “app” being developed for Hypertension.
We remind all researchers that Hypertension can only publish the top 25% or less of your submissions. We look for the best original articles with a sound hypothesis, strong data, and novel findings. We have to say no frequently, but we are always happy to look again at new or improved data from you. Please support Hypertension by sending your best work to the journal, and encourage your colleagues to do the same.
The scientific paradigm underlying the clinical and research specialty that we call “hypertension” is mature and yet in great need of further development. Despite our enormous progress in detailed understanding of the pathophysiology of hypertension and hypertension-related target organ damage, the new drug pipelines in major pharmaceutical companies are dry. This is in the face of millions of people worldwide who are suboptimally treated and, thus, at risk of irreversible late complications, such as stroke, myocardial infarction, and end-stage renal failure. We call on all authors and supporters of Hypertension to bring about new paradigms in translational research and stratified medicine to eliminate late complications of uncontrolled hypertension worldwide. Please join these efforts as an author of original work, a clinical scientist proposing new drug targets, a member or fellow of the American Heart Association Council for High Blood Pressure Research, or in many other roles worldwide, which contribute to better treatment for millions of patients who suffer from the consequences of high blood pressure.
The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.
- © 2012 American Heart Association, Inc.